Skip to content
Hair Pipeline
← Recruiting trials
NCT07402330Early phase 1Withdrawn

Pharmacokinetic Study of DA-020

In the register

The register attaches this trial to DA-001 / DA-002 / DA-005 (Applied Biology), currently at “Phase 1/2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.

What the registry records

Status
Withdrawn
Declared phase
Early phase 1
Sponsor
Applied Biology, Inc.
Participants (registry)
—
Start
April 2026 (planned)
Primary completion
October 2026
Study completion
October 2026
Last registry update
November 2026
Countries
Brazil, Italy

Conditions studied: Chemotherapy Induced Alopecia, Chemotherapy Side Effects

Interventions: DA-020 (0.1%), DA-020 (0.2%), DA-020 (0.5%)

Full record on ClinicalTrials.gov ↗

Other trials of DA-001 / DA-002 / DA-005

  • NCT06762548Phase 3Not yet recruiting

    Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia

  • NCT07033845Early phase 1Withdrawn

    Pharmacokinetic Study of Topical Phenylephrine

  • NCT06501924Phase 3Withdrawn

    Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss

  • NCT07397325Phase 1/2Recruiting

    Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia

  • NCT06648850Phase 2/3Not yet recruiting

    Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.